Company intelligence / Profile preview

Calluna Pharma

Ownership: Private
Development stage: Preclinical

Overview

Calluna Pharma is a clinical-stage biotech company formed from the merger of Oxitope Pharma and Arxx Therapeutics. It develops first-in-class monoclonal antibodies targeting upstream drivers of inflammation and fibrosis. Its lead asset, CAL101—a mAb against S100A4—has completed a successful Phase I trial showing favorable safety and pharmacokinetics with no serious adverse events. The company has four programs in its pipeline addressing high unmet needs in fibrotic and inflammatory diseases. Series A financing raised €75 million to advance multiple candidates into proof-of-concept studies.

Therapeutic areas: PulmonologyNephrologyRheumatologyImmunologyDermatology
Modalities: Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

4 assets

AX-202

3 more assets in the full pipeline.

Partnerships

Partnership with Lilly ExploR&D™ for at least one pipeline program ("CAL103")

Beyond the preview

Go deeper on Calluna Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calluna Pharma.